-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Repare Therapeutics (NASDAQ:RPTX) Shares Gap Up to $14.25
Repare Therapeutics (NASDAQ:RPTX) Shares Gap Up to $14.25
Repare Therapeutics Inc. (NASDAQ:RPTX – Get Rating)'s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $14.25, but opened at $14.74. Repare Therapeutics shares last traded at $14.60, with a volume of 2,101 shares.
Analyst Upgrades and Downgrades
Separately, HC Wainwright lowered their target price on shares of Repare Therapeutics from $38.00 to $25.00 and set a "buy" rating for the company in a report on Thursday, November 17th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $31.50.
Get Repare Therapeutics alerts:Repare Therapeutics Stock Performance
The business has a 50-day moving average of $15.50 and a 200-day moving average of $13.90. The stock has a market capitalization of $634.05 million, a price-to-earnings ratio of -20.70 and a beta of 0.06.
Insider Activity
In other news, Director Davis Jerel sold 250,000 shares of Repare Therapeutics stock in a transaction on Friday, December 9th. The shares were sold at an average price of $16.00, for a total value of $4,000,000.00. Following the transaction, the director now directly owns 2,094,451 shares of the company's stock, valued at approximately $33,511,216. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 33.60% of the company's stock.Hedge Funds Weigh In On Repare Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its position in Repare Therapeutics by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 73,842 shares of the company's stock worth $895,000 after acquiring an additional 600 shares during the period. State Street Corp increased its stake in Repare Therapeutics by 1.2% in the 3rd quarter. State Street Corp now owns 53,475 shares of the company's stock valued at $649,000 after buying an additional 648 shares during the period. Nuveen Asset Management LLC raised its position in Repare Therapeutics by 3.1% during the 3rd quarter. Nuveen Asset Management LLC now owns 21,818 shares of the company's stock worth $265,000 after buying an additional 660 shares during the last quarter. UBS Group AG lifted its stake in shares of Repare Therapeutics by 26.3% in the 3rd quarter. UBS Group AG now owns 3,551 shares of the company's stock worth $43,000 after acquiring an additional 739 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Repare Therapeutics by 5.3% in the first quarter. JPMorgan Chase & Co. now owns 25,039 shares of the company's stock valued at $356,000 after acquiring an additional 1,253 shares in the last quarter. Hedge funds and other institutional investors own 78.19% of the company's stock.
Repare Therapeutics Company Profile
(Get Rating)
Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.
Further Reading
- Get a free copy of the StockNews.com research report on Repare Therapeutics (RPTX)
- Should You Warm up to Generac Stock for the Winter?
- Is Kintara Therapeutics A Hidden Gem?
- 3 High-Yield Dividend Stocks to Hold for the Long Haul
- Cal-Maine Posts Record Quarter, Remain CALM Income Investors
- Tesla Stock: What the Bulls and the Bears Are Getting Wrong
Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Repare Treateutics Inc.(納斯達克代碼:RPTX-GET Rating)的股價在週三開盤前大幅上漲。該股此前收於14.25美元,但開盤報14.74美元。Repare Treateutics的股票最後報14.6美元,成交量為2,101股。
分析師升級和下調評級
另外,HC Wainwright在11月17日週四的一份報告中將Repare Treeutics的股票目標價從38.00美元下調至25.00美元,並為該公司設定了“買入”評級。一位研究分析師將該股評級為持有,四位分析師給予該股買入評級。根據MarketBeat的數據,該股目前的普遍評級為“適度買入”,平均目標價為31.50美元。
到達修復治療學警報:Repare治療公司股票表現
該業務的50日移動均線切入位在15.50美元,200日移動均線切入位在13.90美元。該股市值為6.3405億美元,本益比為-20.70倍,貝塔係數為0.06。
內幕活動
在其他新聞方面,董事戴維斯·傑裡爾在12月9日(星期五)的一筆交易中出售了250,000股Repare治療公司的股票。這些股票的平均價格為16.00美元,總價值為4,000,000.00美元。交易完成後,董事現在直接持有該公司2,094,451股股票,價值約33,511,216美元。這筆交易是在提交給美國證券交易委員會的一份檔案中披露的,該檔案可通過此超鏈接。公司內部人士持有該公司33.60%的股份。對沖基金參與Repare Treeutics
一些對沖基金和其他機構投資者最近改變了他們在該股的頭寸。先鋒集團在第三季度將其在Repare治療公司的地位提高了0.8%。先鋒集團在此期間增持了600股,目前持有73,842股該公司股票,價值895,000美元。道富集團在第三季度增持了Repare Treeutics 1.2%的股份。道富銀行目前持有53,475股該公司股票,價值649,000美元,在此期間又購買了648股。Nuveen Asset Management LLC在第三季度將其在Repare Treeutics的頭寸提高了3.1%。Nuveen Asset Management LLC在上個季度又購買了660股,現在擁有21,818股該公司股票,價值265,000美元。瑞銀集團(UBS Group AG)在第三季度增持了Repare Treateutics 26.3%的股份。瑞銀集團(UBS Group AG)在此期間增持了739股,目前持有該公司3,551股股票,價值43,000美元。最後,摩根大通在第一季度增持了Repare Treeutics的股票5.3%。摩根大通(JPMorgan Chase&Co.)在上個季度增持了1,253股後,目前持有該公司25,039股股票,價值356,000美元。對沖基金和其他機構投資者持有該公司78.19%的股份。
Repare治療公司簡介
(獲取評級)
Repare治療公司是一家臨床階段的精確腫瘤學公司,通過在加拿大和美國使用其合成致命性方法來發現和開發治療方法。該公司使用其SNIPRx,這是一個專有的、全基因組的和支持CRISPR的平臺,以系統地發現和開發專注於基因組不穩定性(包括DNA損傷修復)的高度針對性的癌症療法。
進一步閱讀
- 免費獲取StockNews.com關於Repare治療的研究報告(RPTX)
- 你應該暖身到Generac股票過冬嗎?
- 金塔拉治療公司是一顆隱藏的寶石嗎?
- 長期持有的3只高收益股利股票
- 加州緬因州公佈創紀錄的季度業績,保持冷靜的收入投資者
- 特斯拉股票:公牛和熊隊哪裡出了問題
接受Repare治療日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Repare Treeutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧